

ω,ω' -Urea- and -dithioacetal-derivatives of hypericin

Joachim Zuschrader, Gerald Reiter, Heinz Falk


Institute of Organic Chemistry, Johannes Kepler University, Linz, Austria

Received 10 December 2007; Accepted 18 December 2007; Published online 18 February 2008

© Springer-Verlag 2008

Abstract An ω,ω' -disubstituted hypericin derivative bearing two dicyclohexylurea moieties separated by propionyl chains from the chromophore and an ω,ω' -dithioacetal of hypericin were prepared. Both showed excellent production of oxidizing species comparable to hypericin when irradiated with appropriate light as shown by the photodestruction of bilirubin IX α .

Keywords Hypericin; *N,N'*-Dicyclohexylurea; Photodynamic agent; Dithioacetal; Oxidizing species.



Introduction

Although hypericin (**1**; 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-phenanthro[1,10,9,8-*opqra*]perylene-7,14-dione) is still “number one” of the photodynamic therapy sensitizer candidates, the search for second-generation photosensitizers is still proceeding [1]. This search is targeted at two main issues, namely to shift the absorption wavelength into the area of medicinal lasers on the one hand [1, 2], and to hybridize the hypericin moiety with moieties that modulate the properties of the molecule with *e.g.*, aiming at better water solubility or better interaction with cellular ingredients [3]. In this report we will address the synthesis and properties of an urea appended hypericin derivative having in mind the prominent hydrogen bonding capabilities of its carbonyl unit, and to a thioacetal derivative to explore the influence of saturated heterocyclic sulfur on the photochemical behavior of hypericin (**1**).


Results and discussion

The design of the target molecule was directed by leaving the hypericin moiety as untouched as possible to grant undiminished photochemical properties on the one hand, and a substituted urea unit attached some distance from the chromophore. Thus, we ended up with a hypericin- ω,ω' -dipropionic unit attached to a *N,N'*-dicyclohexylurea (**2**, Scheme 1). An advantage of this kind of attachment is certainly its low hydrolysis potential. On the other hand, a derivative containing un-conjugated saturated sulfur units could provide information on the influence of this atom as compared to corresponding unsaturated conjugated sulfur heterocycles. Thus, we targeted the dithioacetal **3** also (Scheme 1).

Syntheses

Although the preparation of ω,ω' -disubstituted hypericin derivatives usually has to start with the synthesis of the two “halves”, which then are dimerized [1], the synthesis of **2** fortunately could be started

Correspondence: Heinz Falk, Institute of Organic Chemistry, Johannes Kepler University, Altenbergerstraße 69, 4040 Linz, Austria, Europe. E-mail: heinz.falk@jku.at



Scheme 1

with the already known hypericin- ω,ω' -dipropionic acid **4** [4]. The latter was reacted with *N,N'*-dicyclohexylcarbodiimide (*DCCD*) in *THF* solution in presence of triethylamine. This reaction provided the hypericin- ω,ω' -bisacylbis(dicyclohexylurea) **2** in 70% yield. Interestingly enough, we accidentally discovered this reaction when we tried to esterify or amidate the acid **4** by means of *DCCD* (Scheme 2).


For the preparation of the hypericin- ω,ω' -dithioacetal **3** we started from the tri-*O*-methyl protected emodin-aldehyde **5** prepared recently [5] (Scheme 3). By means of the silica-gel/thionyl chloride catalyst compound **5** was efficiently acetalized [6] with 1,3-propanedithiol to yield **6** in 84% yield. This dithioacetal **6** was then reduced at the quinone part in the conventional way using the system SnCl_2/HBr /acetic acid providing the anthrone derivative **7** with 86% yield. Dimerization in analogy to Ref. [7] afforded the ω,ω' -disubstituted protohypericin derivative **8**. Because this product was not stable enough to be purified by chromatography, it was immediately photocyclized and thus gave the targeted hypericin- ω,ω' -dialdehyde dithioacetal **3** in about 50% overall

yield for the last two steps. It might be mentioned that under some of the various conditions designed for recovering the aldehyde function from thioacetals ($\text{AgClO}_4/\text{I}_2$ [8], $\text{Tl}(\text{NO}_3)_3$ [9], and *NBS*/acetone [10]) none could be successfully applied to provide the hypericin- ω,ω' -dialdehyde.


Properties

As could be expected for non-conjugated hypericin derivatives the long-wavelength absorption band of the two derivatives **2** and **3** are only marginally shifted as compared with hypericin (**1**), with the first one a few nm hypsochromically shifted, whereas the latter is more or less absorbing at the same wavelength – both with about the same pattern of the absorption spectra as **1**. The fluorescence spectra are also very similar. The most interesting property with respect to photodynamic therapy is the ability to produce oxidizing species and/or singlet oxygen. We applied the recently developed method of photosensitized destruction of bilirubin IX α to test for this ability [11]. As shown in Fig. 1 both derivatives display similar but slightly diminished activities as hypericin (**1**) itself. In particular, in the case of the saturated sulfur-containing derivative, the photosensitization of oxidizing species seems to be significantly reduced.

In conclusion, we prepared two derivatives **2** and **3** of hypericin (**1**) with two urea and two thioheterocyclic moieties non-conjugatedly attached. Both show comparable photodynamic activity and might be candidates for second-generation photodynamic agents aimed at certain interactions with cell components.



Scheme 2



Scheme 3

Experimental

The characterizations of the products were established using mp (Kofler microscope, Reichert), ^1H NMR (Bruker Avance DPX 200 MHz, DMSO-d_6), IR (Bruker Tensor 27, KBr), MS




Fig. 1 Hypericin derivative sensitized photooxidation of bilirubin IX α : normalized absorption (A/A_0) vs. time curves of solutions of disodium bilirubinate IX α together with the sodium salts of either hypericin (**1**) (—), derivative **2** (---), and derivative **3** (-.-)

(ThermoFinnigan LCQ Deca XP Plus), fluorescence (Varian Carey Eclipse fluorescence), and UV-Vis data (Varian Cary 100 Bio). The production of singlet oxygen/oxidizing species by **1**, **2**, and **3** was monitored by bilirubin-IX α -degradation according to Ref. [11]. The long-wavelength absorption band intensities of the three compounds were made equal by adjusting concentrations to provide comparable light absorptions for the three compounds. *N,N'*-Dicyclohexyl-carbodiimide was obtained from Merck and used as obtained. Compounds **4** and **5** were prepared according to Refs. [4] and [5]. Silica-gel loaded with thionyl chloride was prepared according to Ref. [6].

3,3'-(1,6,8,10,11,13-Hexahydroxy-7,14-dioxo-7,14-dihydro-phenanthro[1,10,9,8-opqra]perylene-3,4-diyl)bis(N-cyclohexyl-N-(cyclohexylcarbamoyl)propanamide) (**2**, $\text{C}_{60}\text{H}_{64}\text{N}_4\text{O}_{12}$)
A solution of 20 mm³ molten *N,N'*-dicyclohexylcarbodiimide in 2 cm³ dry THF was heated to 40°C under Ar atmosphere. After addition of 20 mg **4** (0.03 mmol) dissolved in 10 cm³ dry THF and 20 mm³ triethylamine, the reaction mixture was kept at this temperature for 5 h. By evaporation of the solvent under reduced pressure and subsequent extraction with ethyl acetate/water a black solid was obtained. Purification by means of column chromatography with chloroform:methanol = 10:1 on silica yielded 23 mg **2** (70%). Mp >350°C; R_f = 0.55 (CHCl_3 :MeOH = 5:1); ^1H NMR (500 MHz, DMSO-d_6 , 30°C): δ = 18.48 (s, 2ar-OH), 14.72 (s, 2ar-OH), 14.08 (s, 2ar-OH), 7.77 and 7.79 (s, 2NH, D-exchangeable), 7.45 (s, 2ar-H) ppm, $-\text{CH}_2-$ not observable due to solvent overlap; ESI-MS (negative ion mode): m/z = 1031 ($[\text{M} - \text{H}]^-$); IR (KBr): $\bar{\nu}$ = 3328, 2928, 1628, 1576, 1539, 1449, 1437, 1312, 1271,

1244, 1088, 1045, 892, 641 cm^{-1} ; UV-Vis (80% EtOH, $c = 9.5 \cdot 10^{-5} \text{ mol dm}^{-3}$): λ_{max} (ϵ) = 546 (589), 584 (1421) nm ($\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$); UV-Vis (DMSO, $c = 9.5 \cdot 10^{-5} \text{ mol dm}^{-3}$): λ_{max} (ϵ) = 555 (737), 588 (1284) nm ($\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$); fluorescence (80% EtOH, $c = 2.4 \cdot 10^{-6} \text{ mol dm}^{-3}$, $\lambda_{\text{ex}} = 550 \text{ nm}$): λ_{em} (rel. int.) = 596 (100), 641 (9) nm; fluorescence (DMSO, $c = 1.0 \cdot 10^{-7} \text{ mol dm}^{-3}$, $\lambda_{\text{ex}} = 550 \text{ nm}$): λ_{em} (rel. int.) = 604 (100), 653 (30) nm.

3,4-Di(1,3-dithian-2-yl)-1,3,4,6,8,13-hexahydroxy-phenanthro[1,10,9,8-opqra]perylene-7,14-dione (3, C₃₆H₂₄O₈S₄)

In 2500 cm^3 acetone the raw-product **8** was dissolved and irradiated for 25 min by means of a 700 W high pressure lamp with fluorescence screen (Philips, HPL-N) under stirring and air admission. After evaporation of the solvent the resulting black residue was purified by column chromatography over silica using CHCl_3 :MeOH (3:1) as solvent to yield 73 mg **3** (ca. 50% from **7**). Mp $>350^\circ\text{C}$. TLC: $R_f = 0.65$ (CHCl_3 : $\text{CH}_3\text{OH} = 3:1$), $R_f = 0.44$ ($\text{CH}_3\text{COOC}_2\text{H}_5$: $\text{CHCl}_3 = 2:1$). ^1H NMR (200 MHz, DMSO- d_6 , 30°C ; for comparison reasons the numbering scheme of **1** is retained and is not in accord with the IUPAC numbering scheme of the name above): $\delta = 14.26$ (s, ar-OH), 14.63 (s, ar-OH), 7.70 (s, ar-H5, ar-H2), 6.64 (s, ar-H12, ar-H9), 6.14 (s, 10-CHR₂, 11-CHR₂) ppm; ESI-MS ($\text{CH}_3\text{OH} + 1\% \text{ NH}_3$, negative ion mode): $m/z = 712.8$ ($[\text{M} - \text{H}]^-$); UV-Vis (acetone): $\lambda_{\text{max}} = 326$ (95), 451 (48), 552 (42), 596 (67) nm (rel. int.).

3-(1,3-Dithian-2-yl)-1,6,8-trimethoxyanthracene-9,10-dione (6, C₂₁H₂₀O₅S₂)

A solution of 156 mg **5** (0.48 mmol) in 12 cm^3 benzene, 70 mm^3 1,3-propanedithiol (0.70 mmol) and 93 mg silica-gel loaded with thionyl chloride was stirred under Ar at 60°C for 12 h. The mixture was extracted five times with saturated NaHCO_3 /ethyl acetate, washed several times with distilled water and evaporated under reduced pressure to obtain 170 mg **6** (84%). The purification was achieved by column chromatography over silica using CHCl_3 :MeOH (15:1) as the solvent. Mp $228\text{--}232^\circ\text{C}$; $R_f = 0.82$ (CHCl_3 : $\text{CH}_3\text{OH} = 15:1$); ^1H NMR (500 MHz, DMSO- d_6 , 30°C ; here and below for comparison reasons the numbering scheme of emodin is retained and is not in accord with the IUPAC numbering scheme of the name above): $\delta = 7.78$ (s, ar-H5), 7.52 (s, ar-H7), 7.17 (s, ar-H4), 6.95 (s, ar-H2), 5.54 (s, 6-CHR₂), 3.91 (9H, s, ar-OCH₃), 3.10 (s, R-S-CH₂-R), 2.95 (s, R-S-CH₂-R), 2.75 (s, R-CH₂-R) ppm; ^{13}C NMR (500 MHz, DMSO- d_6 , 30°C): $\delta = 184$ (C9), 181 (C10), 164 (C3), 162 (C1), 159 (C8), 146 (C6), 117 (C7), 118 (C5), 103 (C2), 106 (C4), 56 (ar-OCH₃), 50 (6-CHR₂), 31 (R-S-CH₂-R), 29 (R-CH₂-R) ppm; HSQC (DMSO- d_6 , 30°C): ar-H2 \leftrightarrow C2, ar-H4 \leftrightarrow C4, ar-H5 \leftrightarrow C5, ar-H7 \leftrightarrow C7, 6-CHR₂ \leftrightarrow 6-CHR₂, ar-OCH₃ \leftrightarrow ar-OCH₃, R-S-CH₂-R \leftrightarrow R-S-CH₂-R, R-CH₂-R \leftrightarrow R-CH₂-R; HMBC (DMSO- d_6 , 30°C): C2 \rightarrow ar-H4, C4 \rightarrow ar-H2, C5 \rightarrow ar-H7, 6-CHR₂, ar-H5, ar-H4, ar-H2, C7 \rightarrow ar-H5, ar-H7, C6 \rightarrow 6-CHR₂, C3 \rightarrow ar-OCH₃, C8 \rightarrow ar-OCH₃, C1 \rightarrow ar-OCH₃.

3-(1,3-Dithian-2-yl)-1,6,8-trihydroxyanthracen-9(10H)-one (7, C₁₈H₁₆O₄S₂)

A solution of 110 mg **6** (0.93 mmol) in 16 cm^3 glacial acetic acid, 7.7 cm^3 HBr (47%), and 463 mg $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ were stirred at 90°C under Ar with protection from light for 60 min. Afterwards, the mixture was extracted twice with H_2O /ethyl acetate, and after evaporation of the solvent purification was achieved by column chromatography over silica using CHCl_3 :MeOH (15:1) as the solvent, and finally the residue was dried over night over P_2O_5 to yield 79.5 mg (86%) **7** as a yellow solid. Mp 175°C (dec); $R_f = 0.60$ (CHCl_3 : $\text{CH}_3\text{OH} = 15:1$); ^1H NMR (500 MHz, DMSO- d_6 , 30°C): $\delta = 12.30$ (d, ar-OH), 10.92 (s, ar-OH), 7.02 (s, ar-H5), 6.87 (s, ar-H7), 6.42 (s, ar-H4), 6.24 (s, ar-H2), 5.42 (s, 6-CHR₂), 4.31 (s, R-CH₂-R), 2.95 (d, R-S-CH₂-R), 2.45 (s, R-CH₂-R) ppm; ESI-MS ($\text{CH}_3\text{OH} + 1\% \text{ NH}_3$, negative ion mode): $m/z = 372.8$ ($[\text{M} - \text{H}]^-$).

*10,13-Di(1,3-dithian-2-yl)-1,3,4,6,8,15-hexahydroxydibenzo[*a,o*]perylene-7,16-dione (8, C₃₆H₂₆O₈S₄)*

A mixture of 75 mg **7** (0.21 mmol), 2.8 mg $\text{Fe}_2(\text{SO}_4)_3 \cdot 7\text{H}_2\text{O}$ (0.007 mmol), and 110.4 mg pyridine-*N*-oxide (1.16 mmol) in 2 cm^3 dry pyridine and 110 mm^3 dry piperidine were stirred under Ar with protection from light at 105°C for 1 h. After cooling to room temperature the reaction mixture was poured into 5 cm^3 2 M HCl and stirred for 30 min at room temperature in the dark. After centrifugation the residue was washed three times with 3% HCl and four times with distilled H_2O , and dried over night in vacuum over P_2O_5 resulting in **8** as a black solid. Because **8** proved to be rather unstable (photocyclization), it was immediately photocyclized. UV-Vis (acetone): $\lambda_{\text{max}} = 368$ (86), 449 (40), 547 (45), 584 (48), 629 (37) nm (rel. int.).

References

1. For reviews see: a) Falk H (1999) Angew Chem 111:3306; Angew Chem Int Ed Engl 38:3116; b) Waser M, Falk H (2007) Curr Org Chem 11:547
2. a) Agostinis P, Vantieghem A, Merlevede W, de Witte PAM (2002) Int J Biochem Cell Biol 34:221; b) Mizeret JC, Van den Bergh HE (1996) Laser Surg Med 159
3. Zeng Z, Qiao R, Zhou J, Xia A, Zhang Y, Liu Y, Chen J, Wang X, Zhang B (2007) J Phys Chem B 11:3742
4. Waser M, Popova Y, Etzlstorfer C, Huber W, Falk H (2005) Monatsh Chem 136:1221
5. Salama TA, Lackner B, Falk H (2003) Monatsh Chem 134:1113
6. Kamitori J, Hojo M (1986) J Org Chem 51:1427
7. Mazur Y, Bock H, Lavie D (1991) CA 2,029,993, Chem Abstr 116:6343z
8. Nishide K, Yokota K (1993) Tetrahedron Lett 34:3425
9. Fujita E, Nagao Y (1978) Chem Pharm Bull 26:3743
10. Corey EJ, Erickson B (1971) J Org Chem 36:3553
11. Hagenbuchner K, Falk H (1999) Monatsh Chem 130:1075